サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1361754

創薬における人工知能（AI）の世界市場レポート

Global Artificial Intelligence (AI) in Drug Discovery Market Report
出版日: | 発行: Value Market Research | ページ情報: 英文 286 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
創薬における人工知能（AI）の世界市場レポート
出版日: 2023年10月01日
発行: Value Market Research
ページ情報: 英文 286 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

創薬における人工知能（AI）市場の世界需要は、2023年～2030年の調査期間中にCAGR47.9%で成長し、2022年の11億9,000万米ドルから2030年までに272億5,000万米ドルの市場規模に達すると予測されています。

創薬における人工知能（AI）は、創薬プロセスにおける困難な課題を解決するために、人間の知能をシミュレートする機械を採用する技術です。この技術は新規化合物の発見に役立ち、治療標的の同定やオーダーメイド薬の開発を支援します。このシステムは、薬剤の特定や様々な慢性疾患の重症度軽減に関する洞察の導出など、数多くの用途があります。この市場には、創薬AI販売と関連サービスが含まれます。

市場力学：

ドラッグデリバリー市場におけるAIの成長を促進する主な要因には、クラウドベースのアプリケーションやサービスの利用増加、ブロックバスター医薬品の特許切れ間近などがあります。また、創薬コストを抑制する必要性の高まりや、医薬品開発に要する時間の短縮も需要を押し上げる要因となっています。さらに、新規薬理療法の発見と開発、ライフサイエンス業界の製造能力の拡大により、技術需要も高まっています。しかし、熟練したAI労働者の不足、医療用ソフトウェアの規制要件の曖昧さ、この分野のデータセットの不足など、いくつかの問題が今後数年間のこの業界の成長を妨げると予想されます。とはいえ、異業種間のパートナーシップの頻度が高まっていることは、市場の開拓率に影響を与える主要な促進要因になると思われます。

本レポートでは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を取り上げています。これらのツールは、業界構造を明確に把握し、競合の魅力を世界レベルで評価するのに役立ちます。さらに、これらのツールは、創薬における人工知能（AI）の世界市場における各セグメントを包括的に評価することもできます。創薬における人工知能（AI）産業の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析：

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける創薬における人工知能（AI）市場の現在と将来の需要を強調する地域展望をカバーしています。さらに、本レポートでは、すべての主要地域における個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 創薬における人工知能（AI）：産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 創薬における人工知能（AI）の世界市場分析：提供製品別

  • 概要：提供製品別
  • 実績データと予測データ
  • 分析：提供製品別
  • ソフトウェア
  • サービス

第6章 創薬における人工知能（AI）の世界市場分析：技術別

  • 概要：技術別
  • 実績データと予測データ
  • 分析：技術別
  • 機械学習
  • ディープラーニング
  • 教師あり学習
  • 強化学習
  • 教師なし学習
  • その他の機械学習技術
  • その他の技術

第7章 創薬における人工知能（AI）の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米の売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域の売上分析
    • 概要、実績と予測
    • アジア太平洋地域：セグメント別
    • アジア太平洋地域：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • ラテンアメリカの売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第8章 創薬における人工知能（AI）企業の競合情勢

  • 創薬における人工知能（AI）市場競争
  • 提携・協力・合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第9章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Microsoft Corporation（US）
  • Exscientia（UK）
  • NVIDIA Corporation（US）
  • Schrodinger（US）
  • Atomwise Inc.（US）
  • BenevolentAI（UK）
  • NuMedii（US）
  • Google（US）
  • Insilico Medicine（US）
  • BERG LLC（US）
  • Cloud Pharmaceuticals（US）
  • Cyclica（Canada）
  • Deep Genomics（Canada）
  • IBM（US）
  • BIOAGE（US）
  • Valo Health（US）
  • Envisagenics（US）
  • twoXAR（US）
  • XtalPi（US）
  • Verge Genomics（US）
  • Owkin Inc.（US）
  • Biovista（US）
  • Evaxion Biotech（Denmark）
  • Iktos（France）
  • Standigm（South Korea）
  • BenchSci（Canada）
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Offering (USD MN)
  • Software Market Sales by Geography (USD MN)
  • Services Market Sales by Geography (USD MN)
  • Analysis Market by Technology (USD MN)
  • Machine Learning Market Sales by Geography (USD MN)
  • Deep Learning Market Sales by Geography (USD MN)
  • Supervised Learning Market Sales by Geography (USD MN)
  • Reinforcement Learning Market Sales by Geography (USD MN)
  • Unsupervised Learning Market Sales by Geography (USD MN)
  • Other Machine Learning Technologies Market Sales by Geography (USD MN)
  • Other Technologies Market Sales by Geography (USD MN)
  • Global Artificial Intelligence (Ai) In Drug Discovery Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Artificial Intelligence (Ai) In Drug Discovery Report
  • Market Research Process
  • Market Research Methodology
  • Global Artificial Intelligence (Ai) In Drug Discovery Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Offering
  • Market Attractiveness Analysis by Technology
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Offering (USD MN)
  • Software Market Sales by Geography (USD MN)
  • Services Market Sales by Geography (USD MN)
  • Global Market Analysis by Technology (USD MN)
  • Machine Learning Market Sales by Geography (USD MN)
  • Deep Learning Market Sales by Geography (USD MN)
  • Supervised Learning Market Sales by Geography (USD MN)
  • Reinforcement Learning Market Sales by Geography (USD MN)
  • Unsupervised Learning Market Sales by Geography (USD MN)
  • Other Machine Learning Technologies Market Sales by Geography (USD MN)
  • Other Technologies Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11218721

The global demand for Artificial Intelligence (AI) in Drug Discovery Market is presumed to reach the market size of nearly USD 27.25 BN by 2030 from USD 1.19 BN in 2022 with a CAGR of 47.9% under the study period of 2023 - 2030.

Artificial intelligence (AI) in Drug Discovery is a technology that employs machines to simulate human intelligence to solve challenging issues in the drug discovery process. The technology helps in discovering novel compounds and aids in the identification of therapeutic targets and the development of tailored medications. The system has numerous applications, including deriving insights into identifying drugs and lessening the severity of various chronic diseases. This market includes AI for drug discovery sales and related services.

MARKET DYNAMICS:

Some of the main drivers propelling the growth of AI in the drug delivery market include the rising usage of cloud-based applications and services and the impending patent expiration of blockbuster pharmaceuticals. Additional factors boosting demand are the growing need to control drug discovery costs and less time required for drug development. Further, the technology demand is also rising due to the discovery and development of novel pharmacological therapies and the expanding manufacturing capabilities of the life science industry. However, several problems are anticipated to impede the growth of this industry in the years to come, including a lack of skilled AI workers, hazy regulatory requirements for medical software, and a lack of data sets in this area. Nonetheless, the growing frequency of cross-industry partnerships will be a major driver influencing the market's development rate.

The report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of artificial intelligence ( ai) in drug discovery. The growth and trends of Artificial Intelligence ( AI) in Drug Discovery Industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the artificial intelligence ( ai) in drug discovery market report provides detailed data on the segments by analyzing them at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Offering

  • Software
  • Services

By Technology

  • Machine Learning
  • Deep Learning
  • Supervised Learning
  • Reinforcement Learning
  • Unsupervised Learning
  • Other Machine Learning Technologies
  • Other Technologies

By Application

  • Immuno-Oncology
  • Neurodegenerative Diseases
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Other Applications

By End User

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Research Centers And Academic & Government Institutes

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Artificial Intelligence ( AI) in Drug Discovery market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the artificial intelligence ( ai) in drug discovery market include Microsoft Corporation (US), Exscientia (UK), NVIDIA Corporation (US), Schrodinger (US), Atomwise, Inc. (US), BenevolentAI (UK), NuMedii (US), Google (US), Insilico Medicine (US), BERG LLC (US), Cloud Pharmaceuticals (US), Cyclica (Canada), Deep Genomics (Canada), IBM (US), BIOAGE (US), Valo Health (US), Envisagenics (US), twoXAR (US), XtalPi (US), Verge Genomics (US), Owkin, Inc. (US), Biovista (US), Evaxion Biotech (Denmark), Iktos (France), Standigm (South Korea), and BenchSci (Canada). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Offering
    • 3.7.2 Market Attractiveness Analysis By Technology
    • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET ANALYSIS BY OFFERING

  • 5.1 Overview by Offering
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Offering
  • 5.4 Software Historic and Forecast Sales by Regions
  • 5.5 Services Historic and Forecast Sales by Regions

6 . GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET ANALYSIS BY TECHNOLOGY

  • 6.1 Overview by Technology
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Technology
  • 6.4 Machine Learning Historic and Forecast Sales by Regions
  • 6.5 Deep Learning Historic and Forecast Sales by Regions
  • 6.6 Supervised Learning Historic and Forecast Sales by Regions
  • 6.7 Reinforcement Learning Historic and Forecast Sales by Regions
  • 6.8 Unsupervised Learning Historic and Forecast Sales by Regions
  • 6.9 Other Machine Learning Technologies Historic and Forecast Sales by Regions
  • 6.10. Other Technologies Historic and Forecast Sales by Regions

7 . GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 7.3.2. North America By Segment Sales Analysis
    • 7.3.3. North America By Country Sales Analysis
    • 7.3.4. United State Sales Analysis
    • 7.3.5. Canada Sales Analysis
    • 7.3.6. Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 7.4.2. Europe by Segment Sales Analysis
    • 7.4.3. Europe by Country Sales Analysis
    • 7.4.4. United Kingdom Sales Analysis
    • 7.4.5. France Sales Analysis
    • 7.4.6. Germany Sales Analysis
    • 7.4.7. Italy Sales Analysis
    • 7.4.8. Russia Sales Analysis
    • 7.4.9. Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 7.5.2. Asia Pacific by Segment Sales Analysis
    • 7.5.3. Asia Pacific by Country Sales Analysis
    • 7.5.4. China Sales Analysis
    • 7.5.5. India Sales Analysis
    • 7.5.6. Japan Sales Analysis
    • 7.5.7. South Korea Sales Analysis
    • 7.5.8. Australia Sales Analysis
    • 7.5.9. Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 7.6.2. Latin America by Segment Sales Analysis
    • 7.6.3. Latin America by Country Sales Analysis
    • 7.6.4. Brazil Sales Analysis
    • 7.6.5. Argentina Sales Analysis
    • 7.6.6. Peru Sales Analysis
    • 7.6.7. Chile Sales Analysis
    • 7.6.8. Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 7.7.2. Middle East & Africa by Segment Sales Analysis
    • 7.7.3. Middle East & Africa by Country Sales Analysis
    • 7.7.4. Saudi Arabia Sales Analysis
    • 7.7.5. UAE Sales Analysis
    • 7.7.6. Israel Sales Analysis
    • 7.7.7. South Africa Sales Analysis
    • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY COMPANIES

  • 8.1. Artificial Intelligence (Ai) In Drug Discovery Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9 . COMPANY PROFILES OF ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. Microsoft Corporation (US)
    • 9.3.1. Company Overview
    • 9.3.2. Company Revenue
    • 9.3.3. Products
    • 9.3.4. Recent Developments
  • 9.4. Exscientia (UK)
    • 9.4.1. Company Overview
    • 9.4.2. Company Revenue
    • 9.4.3. Products
    • 9.4.4. Recent Developments
  • 9.5. NVIDIA Corporation (US)
    • 9.5.1. Company Overview
    • 9.5.2. Company Revenue
    • 9.5.3. Products
    • 9.5.4. Recent Developments
  • 9.6. Schrodinger (US)
    • 9.6.1. Company Overview
    • 9.6.2. Company Revenue
    • 9.6.3. Products
    • 9.6.4. Recent Developments
  • 9.7. Atomwise Inc. (US)
    • 9.7.1. Company Overview
    • 9.7.2. Company Revenue
    • 9.7.3. Products
    • 9.7.4. Recent Developments
  • 9.8. BenevolentAI (UK)
    • 9.8.1. Company Overview
    • 9.8.2. Company Revenue
    • 9.8.3. Products
    • 9.8.4. Recent Developments
  • 9.9. NuMedii (US)
    • 9.9.1. Company Overview
    • 9.9.2. Company Revenue
    • 9.9.3. Products
    • 9.9.4. Recent Developments
  • 9.10. Google (US)
    • 9.10.1. Company Overview
    • 9.10.2. Company Revenue
    • 9.10.3. Products
    • 9.10.4. Recent Developments
  • 9.11. Insilico Medicine (US)
    • 9.11.1. Company Overview
    • 9.11.2. Company Revenue
    • 9.11.3. Products
    • 9.11.4. Recent Developments
  • 9.12. BERG LLC (US)
    • 9.12.1. Company Overview
    • 9.12.2. Company Revenue
    • 9.12.3. Products
    • 9.12.4. Recent Developments
  • 9.13. Cloud Pharmaceuticals (US)
    • 9.13.1. Company Overview
    • 9.13.2. Company Revenue
    • 9.13.3. Products
    • 9.13.4. Recent Developments
  • 9.14. Cyclica (Canada)
    • 9.14.1. Company Overview
    • 9.14.2. Company Revenue
    • 9.14.3. Products
    • 9.14.4. Recent Developments
  • 9.15. Deep Genomics (Canada)
    • 9.15.1. Company Overview
    • 9.15.2. Company Revenue
    • 9.15.3. Products
    • 9.15.4. Recent Developments
  • 9.16. IBM (US)
    • 9.16.1. Company Overview
    • 9.16.2. Company Revenue
    • 9.16.3. Products
    • 9.16.4. Recent Developments
  • 9.17. BIOAGE (US)
    • 9.17.1. Company Overview
    • 9.17.2. Company Revenue
    • 9.17.3. Products
    • 9.17.4. Recent Developments
  • 9.18. Valo Health (US)
    • 9.18.1. Company Overview
    • 9.18.2. Company Revenue
    • 9.18.3. Products
    • 9.18.4. Recent Developments
  • 9.19. Envisagenics (US)
    • 9.19.1. Company Overview
    • 9.19.2. Company Revenue
    • 9.19.3. Products
    • 9.19.4. Recent Developments
  • 9.20. twoXAR (US)
    • 9.20.1. Company Overview
    • 9.20.2. Company Revenue
    • 9.20.3. Products
    • 9.20.4. Recent Developments
  • 9.21. XtalPi (US)
    • 9.21.1. Company Overview
    • 9.21.2. Company Revenue
    • 9.21.3. Products
    • 9.21.4. Recent Developments
  • 9.22. Verge Genomics (US)
    • 9.22.1. Company Overview
    • 9.22.2. Company Revenue
    • 9.22.3. Products
    • 9.22.4. Recent Developments
  • 9.23. Owkin Inc. (US)
    • 9.23.1. Company Overview
    • 9.23.2. Company Revenue
    • 9.23.3. Products
    • 9.23.4. Recent Developments
  • 9.24. Biovista (US)
    • 9.24.1. Company Overview
    • 9.24.2. Company Revenue
    • 9.24.3. Products
    • 9.24.4. Recent Developments
  • 9.25. Evaxion Biotech (Denmark)
    • 9.25.1. Company Overview
    • 9.25.2. Company Revenue
    • 9.25.3. Products
    • 9.25.4. Recent Developments
  • 9.26. Iktos (France)
    • 9.26.1. Company Overview
    • 9.26.2. Company Revenue
    • 9.26.3. Products
    • 9.26.4. Recent Developments
  • 9.27. Standigm (South Korea)
    • 9.27.1. Company Overview
    • 9.27.2. Company Revenue
    • 9.27.3. Products
    • 9.27.4. Recent Developments
  • 9.28. BenchSci (Canada)
    • 9.28.1. Company Overview
    • 9.28.2. Company Revenue
    • 9.28.3. Products
    • 9.28.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies